Developmental programs that generate the astonishing neuronal diversity of the nervous system are not completely understood and thus present a major challenge for clinical applications of guided cell differentiation strategies. Using direct neuronal programming of embryonic stem cells, we found that two main vertebrate proneural factors, Ascl1 and neurogenin 2 (Neurog2), induce different neuronal fates by binding to largely different sets of genomic sites. Their divergent binding patterns are not determined by the previous chromatin state, but are distinguished by enrichment of specific E-box sequences that reflect the binding preferences of the DNA-binding domains. The divergent Ascl1 and Neurog2 binding patterns result in distinct chromatin accessibility and enhancer activity profiles that differentially shape the binding of downstream transcription factors during neuronal differentiation. This study provides a mechanistic understanding of how transcription factors constrain terminal cell fates, and it delineates the importance of choosing the right proneural factor in neuronal reprogramming strategies.
N ervous systems are composed of a diverse array of neuronal cell types that form functional circuits. This cellular complexity is generated by the combinatorial activity of transcription factors (TFs). Decades of developmental biology studies have identified a handful of basic helix-loop-helix (bHLH) TFs, called proneural factors, that are necessary and sufficient to initiate neurogenesis 1 . In addition to conferring neuronal fate, proneural factors contribute to the specification of neuronal subtype identity 2 . The molecular mechanisms by which different proneural factors control and coordinate neurogenesis and neuronal-subtype specification have begun to be elucidated 2 . However, remaining gaps in our knowledge make it difficult to generate the vast array of clinically relevant neurons for research and clinical applications.
Ascl1 (also known as Mash1) and neurogenin 2 (Neurog2), which are the mammalian homologs of Drosophila achaete-scute complex and atonal genes, respectively, are the two main proneural factors that initiate and regulate neurogenesis in vertebrate nervous systems [1] [2] [3] [4] .
Apart from a few regions in the nervous system where they are coexpressed, these two proneural factors are expressed in a complementary manner and are not interchangeable for neuronal-subtype specification [5] [6] [7] . Proneural factors promote neurogenesis and induce distinct subtype identities, and these functions are conserved across phyla. In Drosophila ectoderm, atonal controls chordotonal organ identity, while achaete-scute genes control external sensory organs 8 . In mice, Ascl1 and Neurog2 are respectively required to specify GABAergic (Ascl1) and glutamatergic (Neurog2) neurons in the forebrain and sympathetic (Ascl1) and sensory neurons (Neurog2) of the peripheral nervous system 5, [9] [10] [11] [12] [13] [14] . Thus, the functional divergence of Ascl1 and Neurog2 is an ancestral trait responsible for the generation of neuronal diversity required in the nervous system that predates the split of vertebrates and invertebrates 15 .
The transcriptional programs that establish terminal neuronal identity consist of generic (pan-) neuronal features that are shared by all neurons and subtype-specific features that are shared by specific classes of neurons 1, 16, 17 . These features are considered to be controlled by the activities of neurogenesis-inducing TFs (including proneural TFs) and TF combinations specific to a particular neuronal subtype [18] [19] [20] . While Ascl1 and Neurog2 can induce neurogenesis in neural-lineage and pluripotent cells [21] [22] [23] , reprogramming of differentiated cells usually couple Ascl1 and/or Neurog2 with additional TFs to promote subtype identity and/or to downregulate the resident transcriptional program [24] [25] [26] . However, this model contrasts with the observation that Ascl-and Neurog-proneural families are the dominant force in controlling neuronal subtype identities when expressed in fibroblasts in combination with other TFs 17 . Thus, to better understand the rules that govern neuronal subtype reprogramming, we must understand the differences in Ascl1-and Neurog2-induced neurogenesis.
Direct programming is an advantageous platform to study how proneural TFs, alone or in combination with other TFs, control neuronal gene regulatory networks. An analysis of astrocyte-toneuronal conversion by Ascl1 and Neurog2 has shown that they initially activate largely non-overlapping genes 27 . Additionally, Ascl1 and Neurog2 can act as 'pioneer factors' in fibroblasts by binding to previously inaccessible regulatory regions and increasing chromatin accessibility following binding 25, 28, 29 . However, it is unclear whether Ascl1 and Neurog2 would have a similar non-overlapping differentiation trajectory when expressed in pluripotent stem cells compared to differentiated cells and whether their proposed pioneering activity would differentially affect the acquisition of generic and subtype-specific neuronal features. To address these questions, the intrinsic differences between Ascl1 and Neurog2 and their effect Articles NATUrE NEUrosciENcE on the downstream neurogenesis must be studied in a controlled environment that allows for a direct and robust comparison of the induced transcriptional and chromatin dynamics.
Here, we investigated the mechanism by which the two bHLH proneural factors Ascl1 and Neurog2 engage with chromatin and affect the activities of TFs expressed downstream of Ascl1 and Neurog2 during neuronal differentiation. We found that Ascl1 and Neurog2 generate neurons by binding to largely different sets of genomic sites when expressed in similar chromatin and cellular contexts. Their divergent binding is due to distinct DNA sequence specificities of the respective bHLH domains toward preferred E-boxes. The initial divergent binding of Ascl1 and Neurog2 results in distinct regulatory landscapes that influence the binding pattern and the regulatory activity of shared downstream TFs in establishing shared (generic) and neuron-specific (subtype-specific) expression profiles. Thus, we speculate that the intrinsic differences in Ascl1-and Neurog2-induced neurogenesis increase the number of possible neuronal types generated during development by differentially altering the chromatin landscapes upon which the widely expressed downstream TFs operate.
Results
Ascl1 and Neurog2 program neuronal fate with distinct neuronal subtype bias. To investigate the intrinsic activities of Ascl1 and Neurog2, we generated two isogenic mouse embryonic stem cell (mESC) lines that express either Ascl1 (iAscl1 or iA) or Neurog2 (iNeurog2 or iN) following doxycycline treatment but are otherwise identical (Fig. 1a) . Induction of Ascl1 and Neurog2 resulted in neuronal differentiation with detectable upregulation of the neuron-specific ßIII-tubulin (Tubb3) within 12 h after induction ( Supplementary Fig. 1a ). iA and iN neurons adopted typical neuronal morphologies, with projections compatible with axonal and dendritic identity expressing neurofilament (NF) and MAP2 proteins, respectively (Fig. 1b) . Both iA and iN neurons responded to KCl-induced depolarization by changing their intracellular Ca 2+ concentration albeit with different dynamics, with iN neurons exhibiting slower decay (Fig. 1c ). In line with previous studies [21] [22] [23] 30 , forced expression of the proneural TFs Ascl1 or Neurog2 triggered a rapid conversion of differentiating mESCs into neurons. Therefore, isogenic iA and iN lines constitute an ideal platform with which to comparatively study the molecular mechanisms of Ascl1-versus Neurog2-induced neurogenesis.
Ascl1 and Neurog2 overexpression transdifferentiates astrocytes into neurons by inducing an early divergent transcriptional profile 27 . To investigate whether Ascl1 and Neurog2 induce neuronal differentiation with similar dynamics during mESC differentiation, we profiled mRNA levels at 12 and 48 h after induction. Around 50% of Ascl1 upregulated genes and 37% of Neurog2 upregulated genes were shared at 12 h (390 genes) ( Supplementary Fig. 1b) . The percentages of commonly upregulated genes increased to 74 and 80% at 48 h for iA and iN neurons, respectively (2,560 genes). Shared upregulated genes were enriched in gene ontology terms associated with generic neuronal features ( Supplementary Fig. 1c) . Moreover, by 48 h Ascl1 and Neurog2 had already activated the expression of genes associated with different neuronal subtypes consistent with their requirement during embryonic development such as noradrenergic (Phox2b and Dbh in iA cells) and sensory neuron markers (Ret and Ntrk1 in iN cells) ( Fig. 1d and Supplementary Fig. 1d ).
To investigate whether the gene expression differences stem from a subset of neurons in the dish, or the majority of iA and iN neurons differ, we performed a single-cell RNA sequencing (scRNA-seq) experiment at 48 h after induction. The vast majority of cells upregulated the generic neuronal markers Tubb3 and Map2 (Fig. 1f) . Confirming the hypothesis that Ascl1 and Neurog2 induce neurogenesis through divergent differentiation paths, iA and iN neurons clustered into two distinct groups on the basis of their transgene expression (Fig. 1e) . The neuronal subtype markers were not homogeneously distributed across either population or largely co-expressed in the same cells ( Fig. 1g; Supplementary Fig. 1d ). For example, noradrenergic (Tfap2b and Phox2b) and cortical interneuron (Tlx3 and Arx) markers were primarily expressed by iA neurons, whereas spinal motor (Vacht and Olig2) and sensory neuron (Ret and Ntrk1) markers were expressed by iN neurons (Fig. 1g) . Thus, while these results are not indicative of complete neuronalsubtype specification, Ascl1 and Neurog2 expression initiates different neuronal differentiation programs even when expressed under similar chromatin and transcriptional states.
Ascl1 and Neurog2 bind to largely distinct sets of sites in the genome. To understand how Ascl1 and Neurog2 induce neuronal differentiation, we captured their initial binding at 12 h after induction, which is the earliest time point when the doxycycline system induces robust expression of these TFs in most cells ( Supplementary  Fig. 1a ). We identified 20,452 and 28,206 binding sites for Ascl1 and Neurog2, respectively. While analysis of the whole dataset produces similar percentages ( Supplementary Fig. 2a ), we focused on the top 10,000 binding sites in each dataset for our downstream analysis to eliminate complications that may arise from comparing chromatin immunoprecipitation (ChIP) assays with sequencing (ChIP-seq) signals with different strengths. The initial binding of Ascl1 and Neurog2 was largely non-overlapping, with 90% of all sites confidently called as differentially bound; that is, Ascl1 and Neurog2 each preferentially bound 45% of the sites (Fig. 2a) . Only 10% of the sites were bound with similar strength by both TFs. We designated the Ascl1 and Neurog2 differentially bound sites as Ascl1-preferred sites (A > N sites) and Neurog2-preferred sites (N > A sites), respectively. Sites that were bound by both TFs were designated as shared sites (A = N sites). Ascl1 pioneer activity is not enough to allow for its invariable binding across cell types because Ascl1 binding in mESCs does not recapitulate its genomic distribution when expressed in fibroblasts 25 ( Supplementary Fig. 2d ). Our data recovered some of the few sites previously described as bound by Ascl1 in mESCs, but this comparison was compromised by the radically different ChIP signal strengths 31 ( Supplementary Fig. 2e ). Thus, in line with Dll1 activation by distinct Ascl1 and Neurog2 enhancers ( Supplementary Fig. 2f ), genome-wide comparison of the two proneural bHLH TFs Ascl1 and Neurog2 showed remarkably different binding profiles under similar chromatin and cellular contexts.
Distinct E-box sequences are enriched at Ascl1-and Neurog2-preferred sites. The extensive lack of overlap between Ascl1 and Neurog2 binding prompted us to investigate the possible mechanisms driving their divergent binding patterns. Chromatin accessibility and DNA sequence are the two main factors that dictate in vivo TF binding to regulatory elements 32 . Ascl1 acts as a pioneer factor; however, pioneering activity for Neurog2 was only proposed indirectly when in combination with small molecules that enhance chromatin accessibility 25, 28 . When we compared 12 h Ascl1 and Neurog2 binding to the previous chromatin accessibility state by assay for transposase-accessible chromatin using sequencing (ATAC-seq), we observed that both TFs engage with previously accessible and inaccessible sites in roughly the same proportion, with 57% and 43% of A > N sites that were previously accessible and inaccessible, respectively (Fig. 2b) . Similarly, 53% and 47% of N > A sites were previously accessible and inaccessible, respectively (Fig. 2b) . Therefore, the divergent Ascl1 and Neurog2 binding patterns are not due to major differences in their intrinsic abilities to bind inaccessible chromatin.
It has been observed that the Drosophila orthologs Scute and Atonal have different E-box targets, and that Ascl1 and Neurog2 regulate Dll1 expression by binding to distinct E-box sequences 33, 34 . Thus, we investigated whether DNA sequence features could 
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NATUrE NEUrosciENcE explain the differences in the binding of Ascl1 and Neurog2. The primary (top-ranked) motifs discovered by MEME in each class of Ascl1-and Neurog2-bound sites were variations of canonical E-boxes, differing primarily in the central two nucleotides (Fig. 2c) . The primary motif discovered at A > N sites contained the consensus sequence CAGSTG (with S representing G/C nucleotides), encompassing the canonical E-box motif CAGCTG, which had been associated with Ascl1 binding in fibroblasts and neural stem cells 25, 30 . Conversely, the primary motif at N > A sites contained the consensus CAKMTG (with K representing G/T nucleotides, and M representing A/C nucleotides). The peaks bound by both TFs (A = N) contained a motif that appeared to be the average between 
NATUrE NEUrosciENcE the motifs found in the other two classes (Fig. 2c) . To further identify discriminative motifs between Ascl1 and Neurog2 binding classes, we deployed SeqUnwinder, a tool designed to search for discriminative motifs across ChIP-seq samples. SeqUnwinder identified variations of the canonical E-box motif (CANNTG) that discriminated between A > N, N > A, and A = N shared sites (Fig. 2d ). CAGSTG and CAKATG motifs were visibly enriched at the A > N and N > A sites when plotted in a 150-bp window around peaks (Fig. 2e) . The CAGSTG motif occurred more than once at the A > N sites, while the CAKATG motif occurred on average once (Fig. 2e) . Specifically, CAGCTG and CAGGTG 6-mers were present at 70% and 62% of the A > N sites, with some sites having both 6-mers as opposed to only 27% and 10% of N > A sites (Fig. 2f) . Conversely, 81% of the N > A sites contained the CAGATG 6-mer sequence, while this 6-mer was present at only 22% of the A > N sites. Of note, only 13% of the N > A sites contained the CATATG motif described for in vitro Neurog2 binding 35 . Finally, roughly half of the A = N sites contained both Ascl1-and Neurog2-preferred 6-mers, suggesting that Ascl1 and Neurog2 bind to different E-boxes even within shared enhancers (Fig. 2f) . Sequences flanking E-boxes have been shown to confer additional specificity to bHLH TFs by affecting the DNA shape 36, 37 . Indeed, there were differences in nucleotide preferences flanking the non-discriminative core E-box (CAGNTG), and A > N sites were associated with larger predicted propeller twist and larger predicted minor groove width at alternate sides of the core E-box motif ( Supplementary Fig. 3a ,b). Thus, Ascl1 and Neurog2 have strong DNA sequence preferences that drive their genomic binding in differentiating mESCs.
bHLH domain controls DNA sequence specificity and neuronalsubtype identity. The basic domain of proneural TFs binds to the major groove of DNA, while the helix-loop-helix (HLH) domain mediates heterodimerization with other HLH proteins 38, 39 . To test whether the bHLH (DNA-binding and dimerization) domain is sufficient to induce the divergent Ascl1 and Neurog2 binding patterns, we generated an inducible mESC line expressing a chimeric Ascl1-Neurog2 TF (A [N] bHLH chimera) by swapping the bHLH domain of Ascl1 with that of Neurog2 (Fig. 3a) . Similar to Ascl1 and Neurog2, the A [N] bHLH chimera generated neurons that responded to KClinduced depolarization and expressed mature neuronal cytoskeleton markers (Fig. 3b,c) .
A bHLH chimera binding sites were also similar to that of Neurog2 sites ( Supplementary Fig. 4a ). For example, the ChIP-seq signal and the k-mer signature of the chimera at the shared (Dll1) and neuron-specific genes, such as NeuroD2 (target of Neurog2) and Dlx2 (target of Ascl1), also resembled that of Neurog2 (Fig. 3e) . Thus, the analysis of the A [N] bHLH chimeric TF demonstrates that the differences in Ascl1 and Neurog2 binding patterns are intrinsic and determined by the amino acid sequence of the bHLH domain.
Although the A[N] bHLH chimera bound to Neurog2-preferred sites driven by its Neurog2 bHLH domain, the rest of its amino acid sequence is identical to Ascl1 (Fig. 3a) . Specific residues outside the bHLH domain of Ascl1 and Neurog2 were shown to behave as rheostatlike modulators following phosphorylation and dephosphorylation for the context-dependent activity of their proneural functions 2, [40] [41] [42] [43] [44] . However, the A [N] bHLH chimera induced a gene expression profile similar to that induced by Neurog2 ( Fig. 3f,g bHLH differentiation trajectory is similar to that induced by Neurog2 (Fig. 3f) . The first two PCA dimensions of individual replicates explained 83% of the variance, with PC1 reflecting the differentiation time and PC2 reflecting the differences in iA and iN neurons. These results demonstrate that the bHLH domain of Neurog2 is both sufficient to drive sequence-specific DNA binding on chromatin and strongly induces subtype-specific gene expression profiles in differentiating mESCs. Thus, the divergent Ascl1 and Neurog2 binding pattern is the main determinant of the bias in the expression of neuronal-subtype genes.
Ascl1 and Neurog2 binding results in differential chromatin accessibility and enhancer activity. The strong binding preference and the likely importance of the binding pattern in controlling the differentiation trajectory of neurons prompted us to investigate the chromatin landscapes that result from the divergent Ascl1 and Neurog2 binding profiles. We examined genome-wide chromatin accessibility dynamics by ATAC-seq before and after the induction of the proneural TFs. A global accessibility analysis revealed that Ascl1 and Neurog2 induce different accessibility landscapes ( Supplementary Fig. 5a ). Mirroring the expression dynamics ( Supplementary Fig. 1b ), the majority of initial accessibility changes were specific to iA or iN neurons ( Supplementary Fig. 5a ). As differentiation proceeded and the downstream program converged, a larger set of common loci gained accessibility ( Supplementary  Fig. 5a ). We also compared the accessibility landscape in Ascl1-induced neurons from stem cells and fibroblasts 45 ( Supplementary  Fig. 5b ). Following the Ascl1 binding differences, the accessibility landscape between these two neuronal differentiations was markedly dissimilar.
Because of the divergent binding pattern and the resulting accessibility differences following proneural TF induction, we sought to investigate whether Ascl1-and Neurog2-preferred sites gain accessibility during differentiation. Proneural sites gained an ATAC-seq signal after Ascl1 or Neurog2 binding, regardless of their accessibility state before TF induction (Fig. 4a) . While Ascl1-preferred sites progressively gained accessibility, Neurog2-preferred sites quickly gained accessibility and remained accessible but lost some ATAC-seq signals at 48 h (Fig. 4b) . Interestingly, A [N] bHLH chimera binding also resulted in a rapid gain of accessibility by 12 h, with a pattern similar to that of Neurog2 ( Supplementary Fig. 5c ). These results demonstrate that, albeit with different dynamics, both bHLH factors induce or maintain regulatory regions in an accessible state. Similarly, independent of the histone 3 lysine 27 acetylation (H3K27ac) status before TF induction, Ascl1 and Neurog2 binding resulted in an increase of H3K27ac at bound sites by 48 h (Fig. 4c,d ). Although we observed a gain of accessibility at the previously inaccessible N > A sites in iA neurons by 48 h, these sites did not gain H3K27ac enrichment (Fig. 4b,d ). In summary, both Ascl1 and Neurog2 bind to active or inactive regulatory elements, and their binding subsequently increases chromatin accessibility and enhancer activity of bound regulatory regions. Thus, the divergent binding of Ascl1 and Neurog2 results in different chromatin accessibility and activity landscapes during Ascl1-or Neurog2-induced neurogenesis.
Distinct chromatin landscapes induced by Ascl1 and Neurog2
affect the binding of the downstream TFs. We hypothesized that the regulatory activity of the TFs expressed downstream of both proneural factors will be conditioned by the distinct chromatin landscapes induced by Ascl1 and Neurog2. Brn2 (a POU and Homeodomain TF; also known as Pou3f2), Ebf2 (a non-basic HLH and zinc finger TF), and Onecut2 (a CUT and Homeodomain TF) are among the widely expressed neuronal TFs in the nervous system that are induced by both Ascl1 and Neurog2 in differentiating (Fig. 5a ). Thus, we analyzed Brn2, Ebf2, and Onecut2 genome-wide binding in iA and iN neurons 48 h after induction of the proneural TFs. Around 60% of the Brn2 and Ebf2 binding sites were shared in iA and iN neurons (iA = iN sites), while roughly 40% of Brn2 and Ebf2 sites were differentially enriched in iA or iN neurons (iA > iN and iN > iA sites) (Fig. 5b,c) . Binding of Brn2 in ESC differentiation is dissimilar to Brn2 in fibroblasts when expressed alongside Ascl1 and Myt1l (Supplementary Fig. 6a ). Among these bHLH chimeric TF generates neurons that express mature neuronal markers MAP2 (green) and NF (purple) 9 d after induction. Scale bar, 50 µm. Similar results were observed in at least n = 2 independent cell differentiations. c, iA [N] bHLH neurons respond to KCl-induced depolarization by changing their intracellular Ca 2+ levels. Thick line represents the average across recordings (from n = 2 independent cell differentiations). 
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TFs, Onecut2 had proportionally fewer differentially bound sites in iA and iN neurons (14%), while the majority of sites bound by Onecut2 were shared in iA and iN neurons (86%) (Fig. 5d) .
If the Brn2, Ebf2, and Onecut2 binding differences are shaped by Ascl1-and Neurog2-induced chromatin landscapes, then their differential binding should correlate with the differentially accessible regions established in iA and iN neurons. Indeed, Brn2, Ebf2, and Onecut2 sites that are differentially enriched in iA neurons (iA > iN) occurred in sites that became differentially accessible in iA neurons (Fig. 5e) . Similarly, differentially bound sites in iN 
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neurons (iN > iA) also occurred in sites that became accessible in iN neurons (Fig. 5g) . Meanwhile, the Brn2, Ebf2, and Onecut2 shared binding sites in iA and iN neurons (iA = iN) exhibited high ATAC-seq read counts in both iA and iN neurons, thus were accessible in both neurons (Fig. 5f) . Furthermore, the Brn2, Ebf2, and Onecut2 differential binding sites in iA neurons (iA > iN) substantially overlapped with Ascl1-preferred binding (A > N sites) (45%, 35%, 29%, respectively, and only <1% of expected overlap by chance) at 48 h (Fig. 6a-c 
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analysis at the differentially bound Brn2, Ebf2, and Onecut2 sites that harbor an E-box motif revealed Ascl1-versus Neurog2-preferred E-boxes along with appropriate cognate motifs for downstream TFs (Fig. 6d,e) . Second, while the downstream TF cognate motifs were enriched at the center of the ChIP-seq peaks, the E-box was depleted at the central peak location (Fig. 6d,e) . However, we noted that the downstream TF cognate motif instances were weaker at differentially bound sites compared with other downstream TF binding sites in iA and iN cells (Supplementary Fig. 6b ). These results support a model in which the differential chromatin accessibility induced by Ascl1 and Neurog2 binding exposes weaker cognate motifs that can then be bound by downstream TFs. Consequently, the activity of widely expressed TFs is not functionally equivalent in all neurons.
Ascl1 and Neurog2 control initial transcriptional changes and bias the regulatory activity of downstream TFs in the acquisition of neuron-specific identity.
To understand how the non-overlapping binding of Ascl1 and Neurog2 induces expression of subtype-specific (neuron-specific) and generic (shared) neuronal genes, we explored the association between binding sites of Ascl1, Neurog2, and downstream TFs with induced gene expression using GREAT. We first investigated the association between differential binding and gene expression at 12 h. This analysis revealed that early (12 h) differential binding of Ascl1 or Neurog2 correlated well with early differentially expressed genes at 12 h (Fig. 7a) . Around 65% and 78% of the Ascl1 or Neurog2 differentially expressed genes at 12 h have at least one A > N or N > A peak within GREATdefined regulatory domains, respectively ( Fig. 7a; Supplementary  Table 1 ). Dividing proneural TF binding into previously accessible and inaccessible regions did not dramatically modify the association with transcription (Fig. 7b) . Thus, the initial divergent Ascl1 and Neurog2 binding correlates with differential gene expression regardless of the previous accessibility state.
The next challenge was to understand how the 10% overlap in Ascl1 and Neurog2 binding results in ~80% overlap in gene expression by 48 h after induction. Sites that were bound by Ascl1 The E values are reported by MEME and represent an estimate of the expected number of motifs with the same log likelihood ratio that one would find in a similarly sized set of random sequences. e. MEME motif search at the 48 h differentially bound Brn2, Ebf2 and Onecut2 sites in iNeurog2 neurons (iN > iA) that overlap with differentially bound Neurog2 sites (N > A) with CAKATG motif.
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and Neurog2 (A = N sites) associated with genes that were upregulated in both types of neurons (Fig. 7a-c) . Additionally, differentially bound Ascl1 and Neurog2 sites (A > N and N > A) were also associated with genes that were upregulated in both neurons (Fig. 7a-c) . Expanding on Dll1 regulation by differential Ascl1 and Neurog2 binding 34 , our results suggest that distinct Ascl1 and Neurog2 regulatory elements are spatially peppered around similar sets of genes, and Ascl1 and Neurog2 induce shared and neuron-specific (subtype-specific) gene expression through different regulatory regions (Supplementary Fig. 6c ).
Ascl1 and Neurog2 drive the majority of the expression differences at early time points. We tested whether the downstream factors contribute to gene expression differences. Shared binding sites of Brn2, Ebf2, and Onecut2 in iA and iN neurons were associated with shared upregulated genes in iA and iN neurons at 48 h (Fig. 7d) . Similarly, differentially bound Brn2, Ebf2, and Onecut2 sites significantly associated with Ascl1-or Neurog2-specific gene expression at 48 h (Fig. 7d) . These results suggest that the initial divergent binding of the proneural TFs biases both binding (Fig. 6 ) and activity of shared downstream TFs, thus contributing to neuron-specific expression profiles.
Discussion
Here, we probed the molecular mechanisms governing the divergent roles played by the proneural factors Ascl1 and Neurog2 during neuronal differentiation. Using direct neuronal programming of isogenic mESCs, we found that these proneural factors influence cell fate in two ways. First, Ascl1 and Neurog2 bind to and regulate distinct sets of regions in the genome, determined by the intrinsic activity of their bHLH domains. Second, because of this initial divergent binding, Ascl1 and Neurog2 induce differential chromatin landscapes that shape the binding and function of the shared downstream TFs during neuronal fate specification. Hence, we speculate that the regulatory activity of the widely expressed shared TFs will not be identical when expressed downstream of Ascl1 or Neurog2 during neurogenesis and reprogramming experiments.
The question of bHLH TF binding specificity is of importance not only for proneural factors but also for bHLH TFs that regulate various developmental events such as myogenesis, hematopoiesis, and pancreatic development 38 . While extensive binding differences are intuitive for TFs that belong to different bHLH families and induce different cell types such as MyoD versus Ascl1 or NeuroD2 31, 46 , it was striking to observe the substantial difference in the genomic binding of the proneural bHLHs Ascl1 and Neurog2 even when expressed in similar chromatin contexts. bHLH dimers acquire specificity by recognizing distinct E-box half sites (CAN-NTG) in DNA 47 . Thus, the non-palindromic Ascl1-and Neurog2-preferred E-boxes (CAGGTG and CAGATG, respectively) enriched at the differentially bound sites could reflect the sites that are bound with their heterodimerization partners.
Several experiments suggest the importance of the bHLH domain for the subtype-specific activity of neural bHLHs 46, [48] [49] [50] . Using an equivalent chromatin and cellular context for a comprehensive analysis of Ascl1-, Neurog2-, and Ascl1[Neurog2] bHLH -induced neurogenesis led us to an interesting observation. That is, the genomic binding, transcriptional output, and even the chromatin accessibility dynamics induced by the Ascl1 [Neurog2] bHLH chimera were similar to that induced by Neurog2. The DNA specificity of the bHLH domain can be further divided by amino acids in mostly the basic domain and helix 1 contacting DNA and helix 2 mediating dimerization 39 . Additional experiments are required to resolve if, in this differentiation system, DNA binding preferences of the amino acids in the basic and helix 1 region or the dimerization surface guides 
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Ascl1 and Neurog2 to different sites. Phosphorylation of certain residues outside the bHLH domain has been shown to alter the proneural activity 42 and the interactions with putative partners of Ascl1 and Neurog2 homologs in Xenopus and in mouse models 40, 41, 43, 44 . Although the controlled mESC differentiation system is ideal for studying the intrinsic differences between these proneural TFs, it might lack the complexity of the extracellular signaling occurring in developing embryos. Alternatively, posttranslational modifications can fine-tune the binding preferences that might have been overshadowed by the high expression levels required to differentiate mESCs into neurons. Divergent Ascl1 and Neurog2 binding induces initially divergent accessibility and expression patterns that later converge on a generic neuronal fate while maintaining subtype-specific differences ( Fig. 1d,g; Supplementary Fig. 1b-d) . We found that shared binding of the proneural TFs and the downstream TFs correlated with upregulation of a generic neuronal program. This divergentto-convergent neuronal differentiation trajectory is in line with previous studies that described NeuroD4 among the common targets regulating the shared genes during astrocyte-to-neuron reprogramming by Ascl1 or Neurog2 27 . The complete cascade of events that lead to this convergence while maintaining some expression differences in astrocyte and pluripotent cell differentiations are yet to be uncovered. Brn2 was proposed to be recruited to its genomewide sites by Ascl1 in neuronal reprogramming of fibroblasts 25 . We report here that both Ascl1 and Neurog2 influence the binding pattern of several downstream TFs. Our findings propose a novel mechanism that links these previous findings: the widely expressed shared TFs contribute not only to generic neuronal program but also to neuron-specific programs by retaining the memory of the initial neurogenesis triggered by divergent binding of Ascl1 and Neurog2 (Supplementary Fig. 7 ). Thus, in addition to the differentially expressed TFs and/or terminal selectors, the role of widely expressed TFs should be considered in determining the aspects of neuronal subtype identity.
The ability of Ascl1 and Neurog2 to substitute for each other varies in different regions of the nervous system 5 . We propose that the intrinsic Ascl1 and Neurog2 differences will have a smaller impact on instructing the neuronal-subtype identity in neuronal progenitors in which the chromatin is strongly pre-patterned for a specific neuronal type. However, when expressed in a permissive chromatin and cellular state, Ascl1 and Neurog2 differentially force the specification of distinct neuronal-subtype identities. These findings provide a mechanistic explanation for the importance of choosing the right proneural factor in neuronal differentiation strategies.
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Methods
Experimental procedures.
Cell line generation and cell differentiation. Inducible cell lines were generated using a previously described inducible cassette exchange (ICE) method 51 . Resulting transgenic lines contain a single-copy insertion of the transgene into an expression-competent (HPRT) locus. The p2Lox-Neurog2 (iNeurog2) plasmid was generated by cloning Neurog2 complementary DNA into p2Lox-Flag plasmid 52 . Likewise, the p2Lox-Ascl1 (iAscl1) plasmid was generated by cloning mouse Ascl1 cDNA into p2Lox-V5 plasmid 53 . To generate the p2Lox-iAscl1 [Neurog2] bHLH chimera, 396 bp of oligonucleotide gBlocks (IDT) fragment encompassing the Neurog2 bHLH domain fused to the carboxyl terminus of Ascl1 with 1× hemagglutinin (HA) tag sequence was synthesized. The Ascl1 amino-terminal fragment was amplified from mouse Ascl1 cDNA. In-fusion cloning (Clontech) was used to clone/fuse Ascl1 N-terminal and gBlocks Neurog2 bHLH-Ascl1 C-terminal-HA in a p2Lox plasmid backbone. The inducible cell lines (iA, iN, and iA[N] bHLH ) were generated by treating the recipient mESCs for 16 h with 1 µg ml -1 doxycycline (Sigma, D9891) to induce Cre recombinase expression to mediate recombination following electroporation of the p2Lox-Ascl1, p2Lox-Neurog2, or p2Lox-iAscl1 [Neurog2] bHLH plasmids. After G418 selection (250 ng ml -1 , Cellgro), cell lines were characterized by performing antibody staining against the tagged transgenic proteins Ascl1-V5 (anti-V5; R960-25), FLAGNeurog2 (anti-FLAG; F1804), and A [N] bHLH -HA (anti-HA; ab9110). The Tubb3::T2A-GFPnls line was generated by designing two single guide RNAs (5′-GCTGCGAGCAACTTCACTT and 5′-GAAGATGATGACGAGGAAT) to target Cas9 to the stop codon on exon 4 of Tubb3. A donor vector containing T2A peptide and green fluorescent protein (GFP) with a C-terminal nuclear localization signal was cloned in frame between ~800 bp Tubb3 homologous arms flanking the stop codon. The coding sequence upstream of the Tubb3 stop codon was amplified with 5′-CCCTACAACGCCACCCTGTCCAT (forward) and 5′-CTTGGGCCCCTGGGCTTCTGATTCTTC (reverse) primers. The 3′5′ untranslated region sequence downstream of the Tubb3 stop codon was amplified with 5′-AGTTGCTCGCAGCTGG (forward) and 5′-CCAGCCTTCCCTGCGTTTTTTTC (reverse) primers. Knock-in clones were selected for GFP expression after neuronal differentiation. The p2Lox-Neurog2 plasmid was nucleofected to Tubb3::T2A-GFPnls ESC line to generate iNeurog2 Tubb3::GFP stable line.
The inducible mESCs were grown in 2i (2-inhibitors) based medium (Advanced DMEM/F12: Neurobasal (1:1) Medium (Gibco), supplemented with 2.5% mESC-grade fetal bovine serum (vol/vol, Corning), N2 (Gibco), B27 (Gibco), 2 mM L-glutamine (Gibco), 0.1 mM ß-mercaptoethanol (Gibco), 1,000 U ml -1 leukemia inhibitory factor (Millipore), 3 mM CHIR (BioVision) and 1 mM PD0325901 (Sigma) on 0.1% gelatin (Milipore) coated plates at 37 °C, 8% CO 2 . To obtain embryoid bodies (EBs), 60-70% confluent mESCs were dissociated using TrpLE (Gibco) and plated in AK medium (Advanced DMEM/F12: Neurobasal (1:1) Medium, 10% Knockout SR (vol/vol) (Gibco), penicillin-streptomycin (Gibco), 2 mM L-glutamine and 0.1 mM ß-mercaptoethanol) on untreated plates for 2 days (day −2) at 37 °C, 8% CO 2 . After 2 days, the EBs were passaged 1:2, and expression of the transgenes was induced by adding 3 µg ml -1 doxycycline (Sigma, D9891) to the AK medium. For differentiating mESC (EB) antibody stainings, RNA-seq, sc-RNAseq, and ATAC-seq experiments, 2-3 × 10 5 cells were plated in each 100-mm untreated dishes (Corning). For ChIP-seq experiments, the same conditions were used, but the seeded cell number was scaled up to 3-3.5 × 10 6 cells in 245 mm × 245 mm square dishes (Corning).
For day-9 attached neuron antibody stainings and calcium recording experiments, EBs induced with doxycycline for 2 days (48 h + doxycycline) were dissociated with 0.05% Trypsin-EDTA (Gibco) and plated on poly-D-lysine (Sigma, P0899) coated 4-well plates. The dissociated neurons were grown in neuronal medium with supplements (Neurobasal Medium supplemented with 2% fetal bovine serum, B27, 0.5 mM L-glutamine, 0.01 mM β-mercaptoethanol, 3 µg ml -1 doxycycline, 10 ng ml -1 GDNF (PeproTech, 450-10), 10 ng ml -1 BDNF (PeproTech, 450-02), 10 ng ml -1 CNTF (PeproTech 450-13), 10 µM Forskolin (Fisher, BP2520-5), and 100 µM IBMX (Tocris, 2845)) at 37 C o , 5% CO 2 . Antimitotic reagents (4 µM 5-fluoro-2′-deoxyuridine (Sigma, F0503) and 4 µM uridine (Sigma, U3003)) were used to kill any residual proliferating cells that might have failed neuronal differentiation.
Immunocytochemistry. EBs were collected and fixed in 4% paraformaldehyde (vol/vol) in PBS. Fixed EBs were cryoprotected in 30% sucrose and were embedded in OCT (Tissue-Tek) and sectioned for staining. Primary antibody stainings were done by incubating overnight at 4 °C, and secondary antibody stainings were done by incubating for 1 h at room temperature. Day-9 attached neuron stainings were done on coverslips coated with poly-D-lysine with the same incubation times. After staining, samples were mounted with Fluoroshield with 4,6-diamidino-2-phenylindole (DAPI; Sigma). Images were acquired using a SP5 Leica confocal microscope. The following primary and secondary antibodies were used: antiTubb3 (Sigma, T2200, 1:2,000); anti-V5 (Thermo Fisher Scientific, R960-25, 1:5,000); anti-Flag (Sigma, F1804; 1:500); anti-Map2 (Abcam, ab5392, 1:1,000); anti-neurofilament (DSHB, 2H3, 1:1,000); anti-HA (Abcam, ab9110, 1:5,000); goat anti-chicken Alexa 488 (Invitrogen, A-11039, 1:1,000); goat anti-rabbit Alexa 568 (Invitrogen, A-11036, 1:1,000); and goat anti-mouse Alexa 647 (Invitrogen, A-21236, 1:1,000).
Calcium imaging. Dissociated iA, iN and iA [N] bHLH EBs (750,000) were plated on 0.001% poly-D-lysine coated 35-mm glass bottom plates (MatTek, P35GC-1.5-10-C) and incubated for 9 days in neuronal medium (see above). To load neurons with calcium indicator, the cells were incubated for 30-60 min with 2 µM Fluo-4 AM (Thermo Fisher) and 0.02% Pluronic F-127 (Invitrogen) in Ringer's solution (150 mM NaCl, 4 mM KCl, 10 mM HEPES buffer, 10 mM glucose, 2 mM MgCl 2 , 2 mM CaCl 2 ) 54 at room temperature 55 . Fluo-4 fluorescence was excited with 488 nm light from a monochromatic Polychrome light source (Till Photonics) and emissions were filtered through a 500-550 nm band-pass filter (Chroma). Fluorescence images were acquired at 10 Hz with a cooled EM-CCD camera (Andor). Fluo-4 fluorescence was measured in regions of interest around the cell body of a given neuron. Bath solution exchanges were performed via a computercontrolled gravity-fed perfusion system (Automate Scientific). Excitation light, image acquisition, and hardware control were executed by the Live Acquisition software package (Till Photonics). Post-acquisition analysis was performed using custom Matlab scripts, which normalized changes in fluorescence to the prestimulus baseline fluorescence, which was computed as the mean of the 20 lowest fluorescence measurements taken before stimulus application.
RNA-seq. Cells were collected 0, 12, and 48 h after doxycycline induction, and RNA was isolated by resuspending in TRIzol reagent (Invitrogen, 15596026) followed by purification using a RNeasy mini kit (Qiagen, 74106). RNA integrity was measured using Agilent High Sensitivity RNA Screentape (Agilent Tech, 5067-5080). RNA (500 ng) was spiked-in (1:100) with ERCC Exfold Spike-in mixes (Thermo Fisher, 4456739) for accurate comparison across samples. Illumina TruSeq LS kit v2 (RS-122-2001; RS-122-2002) was used to prepare RNA-seq libraries. The final quantification of the library before pooling was done using a KAPA library amplification kit (Roche Lightcycler 480). The libraries were sequenced on an Illumina NextSeq 500 using V2 and V2.5 chemistry for 50 cycles (single-end) at the Genomics Core Facility at NYU.
scRNA-seq. Cells (iAscl1-v5 and iNeurog2 Tubb3::GFP) were collected 48 h after doxycycline induction, and washes were done in 1× PBS with 0.04 mg ml -1 BSA (Thermo Fisher, AM2616). Cells were strained through a 30 µM CellTrics filter (cat. no. 04-004-2326) to remove cell clumps. An equal number of iA and iN Tubb3::GFP cells were pooled to have 1,000 cells per µl. A 10× Genomics Chromium Single Cell 3′ library kit was used to generate a single-cell library for a targeted cell recovery rate of 10,000 cells (120262 Chromium i7 Multiplex Kit, 120236 Chromium Single Cell 3′ Chip Kit v2, 120237 Chromium Single Cell 3′ Library and Gel Bead Kit v2). The fragment length distribution of the library was determined using an Agilent High Sensitivity DNA D1000 Screentape (5067-5585) system, and the final quantification of the library before pooling was done using a KAPA library amplification kit (Roche Lightcycler 480). The libraries were sequenced on an Illumina NextSeq 500 High Output using V2.5 chemistry with 26 × 98 bp -150 cycles run confirmation at the genomics core facility at NYU.
ChIP-seq. Cells were collected at 12 h and 48 h after TF induction and fixed with 1 mM DSG (ProtoChem) followed by 1% FA (vol/vol) each for 15 min at room temperature. Pellets containing 25-30 × 10 6 cells were aliquoted and flash-frozen at −80 °C. Cells were lysed in 50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol (vol/vol), 0.5% Igepal (vol/vol), 0.25% Triton X-100 (vol/vol) with 1× protease inhibitors (Roche, 11697498001) at 4 °C. After 10 min, the cells were resuspended in 50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol (vol/vol), 0.5% Igepal (vol/vol), 0.25% Triton X-100 (vol/vol), and incubated at 4 °C. Nuclear extracts were resuspended in cold sonication buffer (50 mM HEPES (pH 7.5), 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate (wt/vol), 0.1% SDS (wt/vol)). Sonication was performed on ice using a Branson 450 digital sonifier (Marshall Scientific, B450CC) at 20% amplitude, and 18 cycles of 30 s on/60 s off into average size of approximately 300 bp. Immunoprecipitation was done overnight at 4 °C on a rotator with Dynabeads protein-G (Thermo Fisher) conjugated antibodies. A sample of 5 µg of the following antibodies were used for immunoprecipitation: anti-Ascl1 (Abcam, ab74065); anti-Neurog2 (Santa Cruz, SC-19233); anti-HA (Abcam, ab9110); anti-Brn2 (Santa Cruz, SC-6029); anti-Ebf2 (R&D, AF7006); anti-Onecut2 (R&D, AF6294); and anti-H3K27ac (Abcam, ab4729). Washes were done subsequently with 1× with sonication buffer (cold), sonication buffer with 500 nM NaCl (cold), LiCl wash buffer (20 mM Tris-HCl (pH 8.0)) (cold), 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate) (cold), and TE buffer (10 mM Tris, 1 mM EDTA, (pH 8)) (cold). Elution was done by adding elution buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 1% SDS) and incubating for 45 min at 65 °C. Eluted sample and input (sonicated, not chromatin from ChIP assays) were incubated overnight at 65 °C to reverse the crosslink. RNA was digested by the addition of 0.2 mg ml -1 RNase A (Sigma) and incubating for 2 h at 37 °C. Protein digestion was performed by adding 0.2 mg ml -1 Proteinase K (Invitrogen) for 30 min at 55 °C. Phenol:chloroform:isoamyl alcohol (25:24:1; vol/vol) (Invitrogen) followed by ethanol precipitation were used for DNA extraction. The pellets were suspended in water and one-third of ChIP DNA (1:100 dilution of input DNA) was used to prepare lllumina DNA sequencing libraries. Bioo Scientific multiplexed adapters were ligated after end repair and was run on each of the subsets of Ascl1, Neurog2, Brn2, Ebf2, and Onecut2 binding sites using parameters "-meme-mod zoops -meme-minw 6 -meme-maxw 20", and default parameters otherwise. Primary motif finding analyses (for example, Fig. 2c ) were performed on 50-bp windows centered on the MultiGPS-defined binding event locations. Motif-finding analysis that aimed to find both primary and secondary motif signals (for example, Fig. 6d ,e) were performed on 150-bp windows centered on the MultiGPS-defined binding event locations. Motif distribution plots (Fig. 6d,e) were produced using the Centrimo function of MEME-ChIP. SeqUnwinder 66 was used for label-specific de novo motif discovery. Briefly, all k-mers with lengths of 4 and 5 were used as predictors. The SeqUnwinder classifier was trained to predict iAscl1-specific, iNeurog2-specific, and shared binding events. The heatmaps associating discovered motifs with each label were produced using SeqUnwinder.
For flanking k-mer analysis, we started with all possible 8-mers with the following restrictions: the 8-mers were restricted to contain the CAGNTG 6-mer subsequence and the remaining 2 characters were picked from the following set {A, T, G, C, N}. These restrictions resulted in a total of 150 8-mers. We used these 150 8-mers as predictors for a logistic regression classifier with L1 regularization. The classifier was trained on Ascl1-and Neurog2-specific binding sites. All nonzero weighted 8-mers were used for further analysis.
DNA shape properties around Ascl1 and Neurog2 sites were calculated using the DNAshapeR R package 67 (v.1.10.0).
TF binding site and ATAC-seq heatmaps. The MetaMaker program from the SeqCode project was used to generate heatmaps (https://github.com/seqcode/ seqcode-core/blob/master/src/org/seqcode/viz/metaprofile/MetaMaker.java). Briefly, each row in a heatmap represents a 1,000-bp window centered on the midpoint of a TF binding event. Reads were extended to 100 bp, and overlapping read counts were binned into 10-bp bins. Color shading between white and a maximum color were used to represent the depth of read coverage in each heatmap. We used a systematic approach to choose the read depth represented by the maximum color for each track. We first calculated the read counts in 10-bp bins at all identified binding sites for the given TFt and then used the 95th percentile value as the maximum value for the color palette. The following are the read depths represented by the maximum color for different heatmaps: Ascl1:- For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Sample size
No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications Mazzoni et al., 2013) . Biologically independent cell differentiations were used as replicates. We used 3 independent biological replicates (n=3) for Ascl1 and Neurog2 ChIP-seq experiments. The rest of the ChIP-seq experiments, all ATAC-seq experiments, antibody stainings, and calcium imaging were performed in 2 independent biological replicates. Most of the RNA-seq experiments were performed in 2 biological replicates except iAscl1 48 (n=5) and EB t0 (n=5) because of the availability of additional replicates performed in the past for other studies.
Data exclusions None
Replication All attempts at replication were successful. For all experiments, replication was achieved through multiple independent cell differentiations.
Randomization Experiments were not randomized and we did not perform any in vivo studies. We compared control and test samples through treatment and genetic information.
Blinding
The blinding of investigators were not performed but different people analyzed the same data.
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